Advocates Pharmaceutical & Healthcare
Advocates Ltd., Pharmaceutical & Healthcare is a global Programme Management and Technical Support Organisation based in Scotland, USA and Hong Kong. Clients include universities, virtual & start-up companies, biotechs, pharmaceutical companies, healthcare organisations and investors involved in developing cures for clinical disorders on a regional basis and with a global focus.
Since 2002, it has been our mission to “accelerate the development pathway towards healthier, extended lives through our competence and capacity to address drug development challenges”.
As a testament to this, our team of scientists, project managers & technical professionals have provided `hands on’ technical support to 17 drug development programmes from discovery to our clients required endpoint, all of which have met their development objectives, whilst maintaining focus on delivery of commercial objectives & investment opportunities.
Discovery to Market Key Services include:
· Grant Funding Support
· Technical Due Diligence / Investor Support
· Project Management
· Discovery & Pre-Clinical Support
· Pharmaceutical Development CMC
· Quality Management
· Regulatory Preparation, Submission & Liaison
· Operational / Commercial CMC
· Supplies / Logistics Management
· Clinical Support
· Medical Devices Expertise
Benefits to our Clients:
· Proven expertise of successfully managing development programmes
· Experienced in all compound classes, the majority of therapeutic areas and routes of administration
· Experts in CMC (Chemistry, Manufacturing & Controls)
· Credible relationships with national regulatory agencies
· Trustworthy relationships with funding bodies
· Bases in UK, USA & HK / trade in local currencies
· We care “caring is a powerful business advantage”
If you would like to discuss any aspect of your drug development needs please email:
Angelina Fisher at: email@example.com, alternatively, please call +44 (0) 7929 671290.
Angelina FisherDirector of Corporate Affairs
Almac provides a comprehensive range of integrated services from research through to commercialisation. Almac is a financially stable, privately owned organisation with over 3,300 employees located within the US and UK. Over 95% of work is repeat business, testament itself to the quality, innovation, efficiency and the high level of customer satisfaction provided.
Almac’s integrated solutions extend from research to commercialisation and include:
Biomarker Discovery & Development:
· Companion Diagnostic Development
· Genomic Services
· Bioinformatics Consultancy
· Proprietary Discovery Arrays
API Services & Chemical Development:
· API Development & Manufacture
· Peptide & Protein Technology
· Accelerated First in Man Solution
· Solid State Services
· Isotope Chemistry
· Preformulation & Early Stage Development
· Scale Up and Late Stage Development
· Clinical Trial Manufacture
· Contained Development & Manufacture
· Physical & Chemical Characterisation
· Method Development & Validation
· API & Drug Product Testing
· Stability Testing
Clinical Trial Supply:
· Comparator Blinding
· Packaging & Labelling
· QP Release
· Global Distribution & Supply Chain Management
· IVR / Web
· Statistical Services
· Manufacturing & Packaging
· Product Launch & Distribution
Come and see us at booth #64
Mr Rick DyerBusiness Development Manager
Dr Rob GrundyDirector Research Alliances, Almac Discovery Ltd
Mr Glyn AllsopBusiness Development Manager
Mr Simon LawrenceVP, Business Development, Galen Ltd
Ms Helen McKeeverProgramme Manager
Mr Stephen BarrManaging Director
Albany Molecular Research, Inc. (AMRI)
For over 21 years AMRI has demonstrated its adaptability as the pharmaceutical and biotechnology industries have undergone tremendous change in response to multiple challenges. This experience, a track record of success and locations in the United States, Europe and Asia now provides our customers with SMARTSOURCINGTM, a full range of value-added opportunities providing customers informed decision-making, enhanced efficiency and more successful outcomes at all stages of the pipeline.
AMRI (NASDAQ: AMRI), provides scientific services, technologies and products focused to the pharmaceutical industry since 1991. The Company’s core business consists of a fee-for-service contract services platform encompassing drug discovery, development and manufacturing services.
Mr Ian TrelfaBusiness Development Manager
Autifony Therapeutics Ltd
Autifony Therapeutics is developing pharmaceutical treatments for hearing disorders, which affect a significant proportion of the population. Autifony ‘s approach is focused on Kv3 potassium channel modulation, a novel mechanism of action. These ion channels regulate neuronal activity within the auditory system, and our new drugs aim to treat age related hearing loss and tinnitus. The lead programme entered Phase I clinical trials in May 2013.
Given Autifony’s focus on modulation of Kv3 channels, which have also been implicated in other neurological and psychiatric disorders, there are opportunities for Autifony to investigate these other indications with compounds with different profiles. Autifony was recently awarded Technology Strategy Board funding to progress the development of a candidate drug for the treatment of schizophrenia, working together with academic collaborators at the Universities of Manchester and Newcastle.
Autifony Therapeutics Limited was formed in 2011 as a spin-out from GlaxoSmithKline. The company is privately funded by leading venture capital investors SV Life Sciences, Imperial Innovations and Pfizer Venture Investments. Autifony’s head office is at the Imperial College Incubator in London, and has a subsidiary with medicinal chemistry and biology labs based in Verona, Italy.
Dr Barbara Domayne-HaymanChief Business Officer
Avillion was registered in London UK in December 2012 and we are fully financed by the venture capital groups Abingworth and Clarus ventues. We are a company focused on co-development and financing of late-stage programs, where we provide partners with 100% financing for regulatory approval studies with the intent of accelerating the approval of drugs in the US and the EU.
We offer partners an unique and attractive option for the advancement of their pipeline- where we incur 100% of the clinical and regulatory risk of a program, thereby enabling partners to limit their P&L burden and have an advantageous financial position (EPS preservation).